Table 5 Examples of nanocarriers for anticancer therapy
From: Nanomaterials for cancer therapy: current progress and perspectives
Nanotechnology platform | Description | Pharmaceutical ingredients | Disease | Status | References |
|---|---|---|---|---|---|
PNP | Decorated with somatostatin analogue | Cetuximab | Colon cancer | Phase 1 | NCT03774680 |
NP | Combined with enzalutamide | Camptothecin | Metastatic castration resistant prostate cancer | Phase 2 | NCT03531827 |
NP | Co-coated drug | Nab-paclitaxel rituximab | B-Cell Non-Hodgkin Lymphoma | Phase 1 | NCT03003546 |
Liposome | Liposome | irinotecan | Small cell lung cancer | Phase 3 | NCT03088813 |
Liposome | Pegylated liposomal carrier | Doxorubicin trastuzumab | HER2-positive metastatic breast cancer | Phase 2 | NCT03933319 |
Nanoemulsion | Photosensitizer in PDT therapy | Aminolevulinic acid nanoemulsion | Basal cell carcinomas | Phase 2 | NCT02367547 |
Quantum dot | Coated with drug | veldoreotide | Breast cancer | Phase 1 | NCT04138342 |
Albumin NP | NP bound albumin (Abraxane) | Paclitaxel | Breast cancer, NSCLC, pancreatic cancer | Approved by FDA | [254] |
Liposome | Liposome (DepoCyt) | Cytarabine | Lymphomatous malignancies | Approved by FDA | [255] |
Liposome | Liposome (Marqibo) | Vincristine sulfate | Acute lymphoblastic leukemia | Approved by FDA | [256] |
Liposome | Liposome (Doxil) | Doxorubicin | HIV-related Kaposi sarcoma, ovarian cancer, multiple myeloma | Approved by FDA | [19] |
Liposome | Liposome (DaunoXome) | Daunorubicin | HIV-related Kaposi sarcoma | Approved by FDA | [257] |
Polymer protein conjugate | Multi-agent chemotherapy-eutic regimen (Oncaspar) | L-asparaginase | leukemia | Approved by FDA | [258] |